A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis

Transplantation

Volumn 81, Issue 6, 2006, Pages 845-852

  Ciancio, Gaetano ^a   Burke, George W ^a   Gaynor, Jeffrey J ^a   Ruiz, Phillip ^a   Roth, David ^a   Kupin, Warren ^a   Rosen, Anne ^a   Miller, Joshua ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Cyclosporine; Mycophenolate mofetil; Renal allograft; Sirolimus; Tacrolimus

Indexed keywords

ANTILIPEMIC AGENT; CREATININE; CYCLOSPORIN A; DACLIZUMAB; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CADAVER DONOR; CADAVER KIDNEY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; INFECTION COMPLICATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POLYOMA VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 33645649901     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203894.53714.27     Document Type: Article

References (25)

1. Gonwa T, Johnson C Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprone versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048.
2. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303.
3. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
4. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
5. Hariharan S, Johnson CP, Bresnahan BA, et al. Imrpoved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
6. Burke JF, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358.
7. European Mycophenolate Mofetil Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391.
8. MacDonald AS. RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
9. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantatton 1995; 59: 655.
10. Humar A, Hassoun A, Kandaswamy R, et al. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842.
11. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244.
12. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate motetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
13. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation 2002; 74: 488.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
15. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 441.
16. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999; 67: 882.
17. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999; 67: 614.
18. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
19. Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4: 2058.
20. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
21. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endrocrinology 2005; 146: 1473.
22. Ciancio G, Burke GW, Suzart K, et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transplant 2003; 3: 1010.
23. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170.
24. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
25. McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65: 87.